New Jersey Finalizes “Gift” Ban of Physicians Working with the Pharmaceutical Industry

Conclusion Companies have until January 15, 2018, to enter into any contracts with New Jersey Health Care providers that may exceed the $10,000 total cap for promotional speaking and consulting payments. Unfortunately, these types of rules often work against their stated purpose which is to fight the “Opioid Crisis” our review of the open payments database showed a modest use of payments to physicians by opioid companies in New Jersey. Rather than consulting with companies to determine the optimal use for their products, NJ physicians will have to pay close attention to their payments or find outside work in the legal industry suing or defending those companies. One part of the rule which will get the most press attention (pens, note pads, clipboards, mugs, or other items with a company or product logo) deals with a practice in which the pharmaceutical industry has not participate in over 10 years. The level of miss information from policymakers can sometimes be baffling. Pharmaceutical Research and Manufacturers of America (PhRMA) also has a code of ethics regarding such gifts. However, as we have seen time and time again, those pre-existing codes and rules which are closely followed by industry, do little to stop the behemoth of the regulatory state from setting in. Key Documents Final Rule 12-22-17 with comments:  LIMITATIONS ON AND OBLIGATIONS ASSOCIATED WITH PRESCRIBER ACCEPTANCE OF COMPENSATION FROM PHARMACEUTICAL MANUFACTURERS  Final New Je...
Source: Policy and Medicine - Category: American Health Authors: Source Type: blogs